propafenone has been researched along with Ventricular Dysfunction, Left in 8 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report the case of a 46-year-old man who developed syncope, a widened QRS interval, and depressed left ventricular systolic function during propafenone therapy for atrial fibrillation." | 7.76 | Syncope, widened QRS interval, and left ventricular systolic depression: coincident with propafenone therapy for atrial fibrillation. ( Grodman, R; Isber, N; Samaan, RA; Sobamowo, HO; Tamburrino, F, 2010) |
| "Pharmacological conversion of paroxysmal atrial fibrillation is frequently necessary." | 6.68 | Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators. ( Buia, G; Fresco, C; Morgera, T; Pavan, A; Pavan, D; Proclemer, A; Vicentini, A, 1996) |
| "We report the case of a 46-year-old man who developed syncope, a widened QRS interval, and depressed left ventricular systolic function during propafenone therapy for atrial fibrillation." | 3.76 | Syncope, widened QRS interval, and left ventricular systolic depression: coincident with propafenone therapy for atrial fibrillation. ( Grodman, R; Isber, N; Samaan, RA; Sobamowo, HO; Tamburrino, F, 2010) |
| "Pharmacological conversion of paroxysmal atrial fibrillation is frequently necessary." | 2.68 | Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators. ( Buia, G; Fresco, C; Morgera, T; Pavan, A; Pavan, D; Proclemer, A; Vicentini, A, 1996) |
| "Electrocardiography (ECG) showed ventricular tachycardia." | 1.35 | A case of myotonic dystrophy presenting with ventricular tachycardia and atrial fibrillation. ( Eroğlu, S; Müderrisoğlu, H; Ozbiçer, S; Ozin, B, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Catapano-Minotti, G | 1 |
| Corsonello, A | 1 |
| Antonelli Incalzi, R | 1 |
| Eroğlu, S | 1 |
| Ozin, B | 1 |
| Ozbiçer, S | 1 |
| Müderrisoğlu, H | 1 |
| Samaan, RA | 1 |
| Sobamowo, HO | 1 |
| Tamburrino, F | 1 |
| Grodman, R | 1 |
| Isber, N | 1 |
| Paech, C | 1 |
| Flosdorff, P | 1 |
| Gebauer, RA | 1 |
| Kowey, PR | 1 |
| Yan, GX | 1 |
| Winkel, E | 1 |
| Kao, W | 1 |
| Kolettis, TM | 1 |
| Naka, KK | 1 |
| Katsouras, C | 1 |
| Michalis, LK | 1 |
| Bourantas, K | 1 |
| Fresco, C | 1 |
| Proclemer, A | 1 |
| Pavan, A | 1 |
| Buia, G | 1 |
| Vicentini, A | 1 |
| Pavan, D | 1 |
| Morgera, T | 1 |
| Hsieh, MH | 1 |
| Chen, SA | 1 |
| Wen, ZC | 1 |
| Tai, CT | 1 |
| Chiang, CE | 1 |
| Ding, YA | 1 |
| Chang, MS | 1 |
1 review available for propafenone and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Pharmacologic and nonpharmacologic options to maintain sinus rhythm: guideline-based and new approaches.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Catheter Ablati | 2003 |
2 trials available for propafenone and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Echocardi | 1996 |
Effects of antiarrhythmic drugs on variability of ventricular rate and exercise performance in chronic atrial fibrillation complicated with ventricular arrhythmias.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Blood Pressure; Chi-Square | 1998 |
5 other studies available for propafenone and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Giant P waves after pharmacological cardioversion of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography; Female; Humans; Hypertrophy, Right Ve | 2009 |
A case of myotonic dystrophy presenting with ventricular tachycardia and atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Defibrillators, Implantable | 2009 |
Syncope, widened QRS interval, and left ventricular systolic depression: coincident with propafenone therapy for atrial fibrillation.
Topics: Alcohol Drinking; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Heart Conduction | 2010 |
Pharmacologic cardiac resynchronization of a 1-year-old boy with severe left ventricular dysfunction.
Topics: Anti-Arrhythmia Agents; Cardiac Resynchronization Therapy; Echocardiography; Electrocardiography; Hu | 2012 |
Transient intraventricular conduction delay associated with concurrent intake of propafenone and antineoplastic agents.
Topics: Acute Disease; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Antineoplastic Agents; Drug Interact | 2003 |